NCT06405490View on ClinicalTrials.gov

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

August 30, 2026

Study Completion Date

December 30, 2026

Conditions
Nanoliposomal IrinotecanCadonilimabOxaliplatinCapecitabineFirst-LineAdvanced CancerPancreatic AdenocarcinomaDrug Use
Interventions
DRUG

Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab

Use the above medications on a regular basis

Trial Locations (1)

Unknown

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER